ASH Annual Meeting and Exposition | Conference

Daratumumab Demonstrates Single-Agent Activity in Smoldering Myeloma

December 13th 2017

Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.

Dr. Flinn on Venetoclax and Obinutuzumab in CLL

December 12th 2017

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.

Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients

December 12th 2017

The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Venetoclax/Rituximab Hits Over 80% 2-Year PFS Rate in CLL

December 12th 2017

The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Dr. Wang on Acalabrutinib Activity in Mantle Cell Lymphoma

December 12th 2017

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses results from the phase II ACE-LY-004 trial, which explored the BTK inhibitor acalabrutinib (Calquence) in patients with refractory mantle cell lymphoma (MCL).

Dr. Neelapu on Updated ZUMA-1 Findings in Non-Hodgkin Lymphoma

December 12th 2017

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the updated findings of the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; Yescarta) for patients with refractory aggressive non-Hodgkin lymphoma.

Dr. Goy Discusses Single-Agent Ibrutinib in MCL

December 12th 2017

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma.

Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL

December 12th 2017

Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.

Atezolizumab Triplet Achieves 75% CR Rate in Frontline Follicular Lymphoma

December 12th 2017

The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.

Combination Regimen Safe, Effective as Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma

December 11th 2017

Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) appeared active and well tolerated for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Rituximab Leads to Faster Response in CLL, But PFS Not Improved

December 11th 2017

Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL.

Acalabrutinib Highly Effective for Refractory MCL

December 11th 2017

Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.

Dr. Gasparetto on Results for Selinexor and Daratumumab in Relapsed/Refractory Multiple Myeloma

December 11th 2017

Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting. Selinexor is an interesting new drug that inhibits Exportin 1 (XPO1), which reactivates some of the tumor suppressor proteins. In the phase 1b portion of the study, investigators aimed to identify the optimal dose of selinexor in combination with daratumumab. Gasparetto says the study included a small number of patients, but demonstrated very encouraging data.

Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma

December 11th 2017

A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.

Dr. Younes on Atezolizumab, Obinutuzumab, and Bendamustine in Follicular Lymphoma

December 11th 2017

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the interim analysis of a study exploring the safety and efficacy of atezolizumab (Tecentriq) in combination with obinutuzumab (Gazya) and bendamustine in patients with previously untreated follicular lymphoma.

PD-1 Inhibitor Cemiplimab Active in B-Lymphoid Malignancies

December 11th 2017

Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.

Axi-Cel Responses Sustained With Longer Follow-Up for NHL

December 10th 2017

Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.

Tisagenlecleucel Continues to Impress in DLBCL

December 10th 2017

The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

BCMA-Directed bb2121 Highly Effective for Myeloma

December 10th 2017

Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.

Frontline Brentuximab Vedotin With AVD Bests ABVD for Advanced HL

December 10th 2017

The phase III ECHELON-1 study in Hodgkin lymphoma compared the use of A+AVD with standard chemotherapy of doxorubicin, bleomycin, vinblastine, and dacarbazine.